Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 18,650 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 18,650 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $25.93, for a total transaction of $483,594.50. Following the transaction, the insider owned 22,129 shares in the company, valued at approximately $573,804.97. The trade was a 45.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $25.70 on Friday. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. The firm has a 50 day moving average price of $33.50 and a 200 day moving average price of $31.69. The company has a market cap of $764.06 million, a price-to-earnings ratio of -30.24 and a beta of 1.09.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The company had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. Sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CSTL. Morgan Stanley raised Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. Robert W. Baird raised their price objective on Castle Biosciences from $41.00 to $44.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Canaccord Genuity Group lifted their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. KeyCorp reiterated an “overweight” rating and set a $50.00 target price on shares of Castle Biosciences in a report on Thursday, January 29th. Finally, Guggenheim increased their target price on shares of Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences has an average rating of “Moderate Buy” and a consensus target price of $47.57.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP purchased a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $82,283,000. AIGH Capital Management LLC acquired a new stake in Castle Biosciences during the 3rd quarter valued at $16,105,000. Summit Partners Public Asset Management LLC lifted its holdings in Castle Biosciences by 164.7% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after buying an additional 658,725 shares in the last quarter. Braidwell LP boosted its position in Castle Biosciences by 125.3% in the 2nd quarter. Braidwell LP now owns 822,735 shares of the company’s stock valued at $16,800,000 after buying an additional 457,488 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Castle Biosciences during the fourth quarter valued at about $11,864,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.